{"type":"trials","record":{"id":41751,"source_id":"clinicaltrials-gov","external_id":"NCT05891548","title":"Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration","brief_summary":"Phase 2b, randomized, double-masked, parallel-group, active-controlled, multicenter, 36-week study designed to assess the safety and efficacy of suprachoroidally administered CLS-AX 1.0 mg with a flexible dosing regimen in participants with neovascular age-related macular degeneration previously treated with intravitreal anti-vascular endothelial growth factor (VEGF) standard of care therapy. Only one eye will be chosen as the study eye.","overall_status":"Completed","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Clearside Biomedical, Inc.","enrollment":60,"countries":["United States"],"start_date":"2023-05-31","completion_date":"2024-08-20","last_update_date":"2025-07-25","source_url":"https://clinicaltrials.gov/study/NCT05891548","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"ODYSSEY","age_range":"50 Years","comparator":"Aflibercept","organization":"Clearside Biomedical, Inc.","interventions":["CLS-AX","Aflibercept"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Evaluations of Outcomes Related to ETDRS BCVA in the Study Eye Over Time — Baseline, Weeks 4, 12, 16, 20, 24, 28, 32 an…","Evaluations of Outcomes Related to Fluid Detected on Optical Coherence Tomography in the Study Eye Over Time — Baseline…","Evaluations of Outcomes Related to Lesion Size on Fundus Fluorescein Angiography in the Study Eye Over Time — Baseline,…","Evaluation of the Number of Study Drug Injections and Supplemental Therapy Injections in the Study Eye Over Time — From…","Evaluation of Serious Adverse Events (SAEs) and Treatment-Emergent Adverse Events (TEAEs) — From first dose of masked s…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","CLS-AX","Aflibercept"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05891548","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-05-31 to 2024-08-20","comparator":"Aflibercept","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.865Z","intervention":["CLS-AX","Aflibercept"],"participants":60,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Evaluations of Outcomes Related to ETDRS BCVA in the Study Eye Over Time — Baseline, Weeks 4, 12, 16, 20, 24, 28, 32 an…","Evaluations of Outcomes Related to Fluid Detected on Optical Coherence Tomography in the Study Eye Over Time — Baseline…","Evaluations of Outcomes Related to Lesion Size on Fundus Fluorescein Angiography in the Study Eye Over Time — Baseline,…","Evaluation of the Number of Study Drug Injections and Supplemental Therapy Injections in the Study Eye Over Time — From…","Evaluation of Serious Adverse Events (SAEs) and Treatment-Emergent Adverse Events (TEAEs) — From first dose of masked s…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41751","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}